Clinical Trial Search

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis — -0.37; -0.44 Score on…

Primary: Pain (at 1 Week): Visual Analogue Scale(0 to 10) — 7.166; 4.5 Units on a scale — p=<0.0001

Primary: Change From Baseline in A1C at Week 18 — -0.48; -0.36; 0.12 percent — p=<0.001

Primary: Change From Baseline 24-hour Urinary Free Cortisol Level — 49.5; 39.6; 49.8; 1.5 mcg/hour — p=0.258

Primary: Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females) — 81.8; 80.9; 87.8; 82.8…

Primary: Total Hip Bone Mineral Density Percent Change From Baseline at Month 12 — 2.6; 3.5 Percent Change from Baseline — p=<0.0001

Primary: Percentage of Participants With Treatment Failure Through Week 48 — 21.3 Percentage of Participants

Primary: A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment — 36 Participants

Primary: Participants Who Experienced Adverse Event(s) — 23; 68; 85 Participants

Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants

Primary: Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery — 5.2; 5.4; 4.7; 5.4 scores on scale — p=0.0668

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 177; 32 Participants

Primary: Complete Clinical Response — 85; 103; 86 participants

Primary: Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series — 1.33…

Primary: Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-naïve, Diabetic Subjects. — -0.83; -1.09 Percentage of change of…